Skip to Content

Segall Bryant & Hamll Intl Eq Retl CIQRX

Medalist Rating as of | See Segall Bryant & Hamill Investment Hub
  • NAV / 1-Day Return 10.80  /  −0.28 %
  • Total Assets 2.5 Mil
  • Adj. Expense Ratio
    1.140%
  • Expense Ratio 1.140%
  • Distribution Fee Level Above Average
  • Share Class Type No Load
  • Category Foreign Large Blend
  • Investment Style Large Value
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield
  • Turnover

USD | NAV as of May 02, 2024 | 1-Day Return as of May 02, 2024, 12:17 AM GMT+0

Morningstar’s Analysis CIQRX

Will CIQRX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Segall Bryant& Hamll Intl Eq Retl's Average People Pillar and Process Pillar ratings result in a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings CIQRX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 14.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Novartis AG Registered Shares

2.14 52,498
Healthcare

ASML Holding NV

1.82 44,591
Technology

Shell PLC

1.62 39,681
Energy

Novo Nordisk A/S Class B

1.52 37,326
Healthcare

GSK PLC

1.51 37,142
Healthcare

Honda Motor Co Ltd

1.28 31,464
Consumer Cyclical

Roche Holding AG

1.18 29,107
Healthcare

Canon Inc

1.17 28,661
Technology

Nestle SA

1.16 28,582
Consumer Defensive

Volvo AB Class B

1.12 27,503
Industrials